title: Anti-diabetic compounds and their patent information: an update.
abstract: The increasing epidemic of diabetes mellitus around the globe is increasing the risk of various other chronic diseases i.e. coronary artery diseases, myocardial infarction, hypertension, dyslipidemia and number of other complicated disorders. Diabetes mellitus is clinically characterized by a marked increase in blood glucose levels and is associated with mild hyperlipidemia. Although the prevalence of this health ailment is increasing dramatically, various therapeutic compounds have been developed to treat this disease that is available in the market as synthetic, formulated and combined forms. Recently, various compounds have come through preclinical studies and shown the therapeutic efficacy of using multiple/ specific drug targets. Recent research approaches have been based on receptors targeting, islet cell transplantation, gene expression profiling, glucagon-like peptide-1, dipeptidyl peptidase IV inhibitors, insulin therapy, modulators of peroxisome proliferator-activated receptors (PPAR), glucagon receptor antagonists, insulin analogues, sensitizers and combination therapies. Furthermore various, latest findings claimed to identifying new anti-diabetic regimens with novel mechanism of action are being developed. This review provides an update on the use of approaches to the development of preventive and therapeutic strategies against diabetes and recent patents that could develop into novel therapeutics available to the clinical success for the management of the disease.
authors.affiliation: Department of Biochemistry, APS University, Rewa, Madhya Pradesh, India.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Pandey
authors.forename: Narendra
authors.initials: N
authors.lastname: Kumar
authors.forename: Mukesh
authors.initials: M
authors.lastname: Yadav
authors.forename: Ravinder
authors.initials: R
authors.lastname: Nagpal
authors.forename: Shalini
authors.initials: S
authors.lastname: Jain
authors.forename: Hariom
authors.initials: H
authors.lastname: Yadav
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000096:biosynthesis; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation; D058990:Molecular Targeted Therapy; D010330:Patents as Topic; D047492:Peroxisome Proliferator-Activated Receptors / Q000037:antagonists & inhibitors
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D047492:Peroxisome Proliferator-Activated Receptors; D052216:Glucagon-Like Peptide 1